NASDAQ:ZFGNZafgen Stock Price, Forecast & News

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN shares have increased by 1,305.7% and is now trading at $11.95. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Zafgen.

Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Zafgen.

Zafgen Inc (NASDAQ:ZFGN) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. View Zafgen's earnings history.

3 analysts have issued twelve-month target prices for Zafgen's stock. Their forecasts range from $0.78 to $0.78. On average, they anticipate Zafgen's share price to reach $0.78 in the next year. This suggests that the stock has a possible downside of 93.5%. View analysts' price targets for Zafgen.

News coverage about ZFGN stock has been trending somewhat negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zafgen earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Zafgen.

Some companies that are related to Zafgen include I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Myovant Sciences (MYOV), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Akebia Therapeutics (AKBA), Ironwood Pharmaceuticals (IRWD), Epizyme (EPZM), BELLUS Health (BLUSF), Intra-Cellular Therapies (ITCI), Zymeworks (ZYME), Zogenix (ZGNX), MacroGenics (MGNX), INDIVIOR PLC/S (INVVY) and Intercept Pharmaceuticals (ICPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), SCYNEXIS (SCYX), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Esperion Therapeutics (ESPR) and Gilead Sciences (GILD).

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $11.95.

Zafgen has a market capitalization of $447.77 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

The official website for Zafgen is www.zafgen.com.

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]